Eiko Lifesciences Limited Confirms Non-Applicability of SEBI Large Corporate Debt Framework

Eiko lifesciences Limited has formally notified BSE Limited about its status regarding SEBI's regulatory framework for large corporate debt securities. The company submitted its annual disclosure on April 09, 2026, clarifying its position under the Securities and Exchange Board of India's guidelines for fund raising through debt instruments.

Regulatory Compliance Status

The company has confirmed that as of March 31, 2026, it does not meet the criteria to be classified as a Large Corporate under SEBI regulations. This determination is based on the provisions outlined in SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, along with its subsequent amendments.

Parameter	Details
Assessment Date	March 31, 2026
Classification Status	Not a Large Corporate
Applicable Framework	SEBI Large Corporate Debt Securities
Disclosure Requirement	Not Applicable

SEBI Framework Non-Applicability

Since Eiko Lifesciences Limited does not qualify as a Large Corporate under the specified criteria, the regulatory framework for fund raising by issuance of debt securities by large corporates does not apply to the company. This exemption has significant implications for the company's compliance obligations.

The non-applicability means that Eiko Lifesciences Limited is not required to comply with the specific disclosure requirements mandated for large corporates under this framework. The company is therefore exempt from filing both initial disclosures and annual disclosures that would otherwise be mandatory for entities classified as Large Corporates.

Regulatory References

The disclosure submission references multiple SEBI circulars that govern the large corporate debt framework:

SEBI Circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023
SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021
SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

Corporate Governance

The disclosure was signed by Chintan Doshi, Company Secretary and Compliance Officer, with membership number A 36190. The submission was digitally signed on April 09, 2026, demonstrating the company's commitment to maintaining proper corporate governance standards and regulatory compliance.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.11%	-4.14%	+0.80%	-1.23%	-3.03%	-28.27%

Eiko Lifesciences Limited has completed a significant preferential allotment, with promoter Bhavesh Dhirajlal Tanna disclosing substantial acquisition of shares under SEBI regulations. The company allotted 6,25,000 equity shares and 29,50,000 warrants to promoters and investors, with the Board of Directors approving the allotment on February 24, 2026.

Bhavesh Tanna's Substantial Acquisition

Bhavesh Dhirajlal Tanna, promoter of Eiko Lifesciences Limited, has acquired 4,50,000 equity shares representing 3.14% on non-diluted basis and 2.60% on diluted basis through preferential allotment. The acquisition was made at Rs. 55 per share on February 24, 2026, along with 15,50,000 warrants convertible into equity shares.

Parameter	Before Acquisition	After Acquisition	Change
Equity Shares Held	3,90,000	8,40,000	+4,50,000
Non-Diluted Holding	2.84%	5.86%	+3.02%
Diluted Holding	2.84%	4.86%	+2.02%
Warrants Acquired	-	15,50,000	+15,50,000

Complete Preferential Issue Structure

The total preferential issue comprised 6,25,000 equity shares with a face value of Rs. 10 each at Rs. 55 per share, raising Rs. 3,43,75,000. Additionally, 29,50,000 warrants were allotted, each convertible into one equity share at Rs. 55 per share.

Allottee Category	Equity Shares	Warrants	Percentage Acquired
Promoter (Bhavesh Dhirajlal Tanna)	4,50,000	15,50,000	3.14% (non-diluted)
Promoter Group (Lenus Finvest)	1,75,000	1,50,000	1.22% (non-diluted)
Non-Promoter Entities	-	12,50,000	-
Total	6,25,000	29,50,000	-

Post-Conversion Holdings and Share Capital Impact

Upon conversion of all warrants, Bhavesh Tanna's aggregate holding would reach 23,90,000 shares, representing 13.82% of the diluted share capital. The company's equity share capital increased from Rs. 13,72,08,540 to Rs. 14,34,58,540 after the preferential allotment.

Share Capital Details	Amount (Rs.)	Equity Shares
Before Acquisition	13,72,08,540	1,37,20,854
After Acquisition	14,34,58,540	1,43,45,854
Total Diluted Capital	17,29,58,540	1,72,95,854

The disclosure was submitted under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The preferential issue received approval from BSE Limited, and all newly allotted shares rank pari-passu with existing equity shares, ensuring equal rights for all shareholders.